Article Versions Notes

Mezi S, Botticelli A, Scagnoli S, Pomati G, Fiscon G, De Galitiis F, Di Pietro FR, Verkhovskaia S, Amirhassankhani S, Pisegna S, et al. The Impact of Drug–Drug Interactions on the Toxicity Profile of Combined Treatment with BRAF and MEK Inhibitors in Patients with BRAF-Mutated Metastatic Melanoma. Cancers. 2023; 15(18):4587. https://doi.org/10.3390/cancers15184587

Mezi, Silvia, Andrea Botticelli, Simone Scagnoli, Giulia Pomati, Giulia Fiscon, Federica De Galitiis, Francesca Romana Di Pietro, Sofia Verkhovskaia, Sasan Amirhassankhani, Simona Pisegna, and et al. 2023. "The Impact of Drug–Drug Interactions on the Toxicity Profile of Combined Treatment with BRAF and MEK Inhibitors in Patients with BRAF-Mutated Metastatic Melanoma" Cancers 15, no. 18: 4587. https://doi.org/10.3390/cancers15184587

Mezi, S., Botticelli, A., Scagnoli, S., Pomati, G., Fiscon, G., De Galitiis, F., Di Pietro, F. R., Verkhovskaia, S., Amirhassankhani, S., Pisegna, S., Gentile, G., Simmaco, M., Gohlke, B., Preissner, R., & Marchetti, P. (2023). The Impact of Drug–Drug Interactions on the Toxicity Profile of Combined Treatment with BRAF and MEK Inhibitors in Patients with BRAF-Mutated Metastatic Melanoma. Cancers, 15(18), 4587. https://doi.org/10.3390/cancers15184587